In-Vivo Animal Studies for
Biopharmaceuticals
At AAL Biosciences, in-vivo research forms the backbone of biopharmaceutical safety and efficacy evaluation. Our studies are built on GLP-compliant systems, ethical rigour, and validated scientific frameworks, giving innovators the confidence to move their molecules forward with clarity and control.
Using internationally aligned protocols and a team led by ABT-certified toxicologists, we deliver high-quality data for IND submissions, biosimilar development, novel therapeutics, and global regulatory pathways. From early toxicology to deep pharmacokinetic insights, our in-vivo capabilities help you understand how your compound behaves within living systems, safely, predictably, and with scientific integrity.
Necessity of In Vivo Studies
In vivo studies remain indispensable for biopharmaceutical development. Here’s why they matter:
Provides Real Biological Insight:
Reveals how a drug interacts with complex organ systems, metabolism, and physiological pathways.
Supports Regulatory Approvals:
Generates mandatory safety and efficacy data required for global submissions, including FDA, EMA, CDSCO, and ICH guidelines.
Refines Dose Selection & Safety Margins:
Helps determine safe exposure levels, therapeutic windows, and long-term tolerability.
Validates Therapeutic Potential:
Disease and efficacy models demonstrate the real-world performance of drug candidates.
Enables Translational Decision-Making:
Bridges preclinical findings with clinical strategy, reducing risk during human trials.
Area of Expertise
